MedPath

Phase II Study for Robot Assisted Distal Gastrectomy

Phase 2
Conditions
Early Gastric Cancer
Interventions
Device: Robot assisted distal gastrectomy (DaVinci)
Registration Number
NCT01504997
Lead Sponsor
Shizuoka Cancer Center
Brief Summary

The aim of this study is to clarify safety of robot assisted distal gastrectomy with lymph node dissection in patients with stage Ia early gastric cancer.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
23
Inclusion Criteria
  1. Biopsy specimen from the primary lesion shows adenocarcinoma
  2. Diagnosed as Stage IA early gastric cancer according to the preoperative esophagogastroduodenoscopy and computer tomography
  3. Endoscopic submucosal dissection is not indicated
  4. Tumor was located within lower two thirds of stomach
  5. Not having duodenal invasion
  6. Eastern clinical oncology group performance status is 0 or 1
  7. Body mass index is lower than 30
  8. No prior laparotomy
  9. No prior chemotherapy or radiation including those for other cancers
  10. Fulfil all following conditions WBC > 3,000/mm3 Plt > 100,000/mm3 AST < 100 IU/L ALT < 100IU/L T.Bil < 2.0 g/dl Cre < 1.5mg/dl
Exclusion Criteria
  1. Having other active cancers
  2. Possibly pregnant, or breast feeding woman
  3. with psychiatric disorder
  4. Receiving steroids
  5. With Acute myocardial infarction in 6 months or with unstable angina
  6. With uncontrolled hypertension
  7. With uncontrolled diabetes mellitus
  8. With pulmonary disease which require continuous oxygen therapy

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Robot assisted distal gastrectomyRobot assisted distal gastrectomy (DaVinci)patients who received robot assisted distal gastrectomy
Primary Outcome Measures
NameTimeMethod
The Incidence of Post-operative Intra-abdominal Infectious ComplicationsParticipants will be followed for the duration of hospital stay, an expected average of 10 days
Secondary Outcome Measures
NameTimeMethod
Relapse Free Survival5 years
Incidence of Adverse EventsParticipants will be followed for the duration of hospital stay, an expected average of 10 days
Overall Survival5 years
Completion Rate of Robot Assisted SurgeryDuring the surgery, an expected average of 5 hours

Trial Locations

Locations (1)

Shizuoka Cancer Center

🇯🇵

Shizuoka, Japan

© Copyright 2025. All Rights Reserved by MedPath